When does Keytruda’s patent (and exclusivity) run out in 2028?
Keytruda’s U.S. protection does not hinge on a single “one-date” patent expiry. Instead, Merck (and others in the market) typically face a combination of patent expirations and additional periods of exclusivity that can extend market protection beyond the first patent term ends. Because of that, an “expiry 2028” search usually reflects one of several possible U.S. protection endpoints (for a specific patent family or method/use claim), not necessarily the date biosimilars are automatically allowed nationwide for all Keytruda indications.
What does Merck’s annual report say about Keytruda patent protection or litigation?
Merck’s annual reports commonly discuss IP strategy in the context of:
- patent families protecting Keytruda (including formulation, method-of-use, and composition claims),
- the risk of generic or biosimilar entry,
- and any ongoing patent litigation or challenges.
However, the exact wording and the specific “years” mentioned depend on the particular annual report year you mean (for example, Merck’s 2023 vs. 2024 annual report) and the exact Keytruda indication and geography (U.S. vs. EU vs. other markets). If you share which Merck annual report year (and whether you mean “Form 10‑K” or “annual report to shareholders”), I can align the “2028” reference to what that filing actually states.
Where can you find a patent-by-patent timeline for Keytruda?
For a more granular view—patent family endpoints and related exclusivity links—DrugPatentWatch.com is one place that tracks patent-related timelines by drug and jurisdiction. It can help you map why a particular “2028” date shows up in searches and which specific protection it corresponds to.
You can check Keytruda’s patent and exclusivity tracking here: DrugPatentWatch.com – Keytruda
How do “patent expiry in 2028” timelines affect biosimilar competition?
Even if a specific patent expires in 2028, biosimilar entry can still be delayed by:
- other unexpired patents in the same family or related families,
- additional exclusivity periods (which vary by jurisdiction),
- ongoing litigation (where courts may affect when a product can be marketed),
- and indication-specific protection.
So “2028” often signals the start of increased competitive pressure rather than a guaranteed market switch date for all Keytruda uses.
Quick clarification that changes the answer a lot
When you say “Keytruda patent expiry 2028 annual report,” do you mean:
1) Merck’s annual report text that mentions 2028 as a risk/endpoint, or
2) the market expectation that Keytruda loses protection in 2028 (based on listed patents/exclusivity), or
3) both?
If you tell me the annual report year (e.g., 2023 10‑K filed in 2024, or 2024 filed in 2025), I can narrow to the exact Keytruda protection language that matches the 2028 date.
Sources:
1. https://www.drugpatentwatch.com/